Terns Pharmaceuticals Launches $400 Million Public Offering

Terns Pharmaceuticals launched a registered public offering of $400 million in common stock (and, for certain investors, pre-funded warrants), with underwriters granted a 30-day option to purchase up to an additional $60 million; all securities will be sold by the company. Net proceeds are earmarked to fund research, clinical development and manufacturing for key programs including TERN-701 and initial preparations for a potential commercial launch, with remaining proceeds for working capital and general corporate purposes; Jefferies, TD Cowen and Leerink Partners are lead book-runners. Terns shares slipped over 3% in pre-market trading after closing at $40.23, following a 37% jump the prior session.

Analysis

Terns Pharmaceuticals announced a registered public offering of $400 million in common stock and, for certain investors, pre-funded warrants, with underwriters granted a 30-day option to purchase up to an additional $60 million; Jefferies, TD Cowen and Leerink Partners are the lead book-runners. All securities will be sold by the company and Terns stated net proceeds will support research, clinical development and manufacturing of key programs including TERN-701 and initial preparations for a potential commercial launch, with remaining funds for working capital and general corporate purposes. The stock moved lower in pre-market trading by more than 3% after closing at $40.23, which followed a 37.02% increase the prior session, signaling investor concern about near-term dilution despite recent momentum. The size of the raise and the presence of pre-funded warrants create a material potential supply overhang; final pricing, mix between shares and pre-funded warrants, and whether the $60 million overallotment is exercised will determine actual dilution and market impact going forward.

Key Decisions for Investors

• Reassess position size immediately and consider trimming exposure or implementing short-term hedges given the announced $400M offering and the >3% pre-market reaction after a 37% prior-session rally
• Monitor final deal pricing, the allocation between common shares and pre-funded warrants and any exercise of the 30-day $60M overallotment because these elements determine ultimate dilution and post-offering float
• Tie any decision to add exposure to TERN to near-term clinical or commercial de-risking events for TERN-701 and to company updates on execution of the stated use of proceeds